510(k) · Cleared
ClearedVisiRad XR
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Imidex, Inc. · MYN Analyzer, Medical Image
Cleared on Aug 3, 2023 as substantially equivalent to K201560 (Samsung Electronics Co., Ltd., 2021) after a 304-day review. Its family tree reaches back 2 generations to 2001.
- Decided
- Aug 3, 2023
- Review
- 304 days
- Class
- Class II
- Product code
- MYN
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 2 generations to P000041 (2001). No later device cites it as a predicate yet.
View FIG. 1 as a table
Line of descent and top descendants
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in MYN? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new MYN device
- #1 K210365 Second Opinionscore 29.9 · 1 generation · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K201560 | Auto Lung Nodule DetectionSummary page 4…zer Device Classification: Class II, 21 CFR 892.2070 Product Code: MYN 4 Predicate Device Name: Samsung Auto Lung Nodule Detection, K201560 Device Classification: Class II, 21 CFR 892.2070 Product Code: MYN 5 Device Description 5.1 Vis… | 2021 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 22 years and passes through 3 companies; a new generation was cleared every 20.1 years on median.
- None of the 2 ancestors has a recall.
- 2 other devices also cite its predicate K201560.
How does its category compare?
All MYN devicesMYN Analyzer, Medical Image: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.
FDA decisions per year · MYN
14in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · MYN
210in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · MYN
No recall names MYN since 2007.
Adverse event reports per year · MYN
2in 2025
MAUDE reports naming product code MYN, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 5 | — | 0 | 0 |
| 2008 | 2 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 2 | — | 0 | 0 |
| 2011 | 1 | — | 0 | 0 |
| 2012 | 6 | — | 0 | 0 |
| 2013 | 4 | — | 0 | 0 |
| 2014 | 3 | — | 0 | 0 |
| 2015 | 3 | — | 0 | 0 |
| 2016 | 2 | — | 0 | 0 |
| 2017 | 3 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 1 |
| 2019 | 1 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 2 | — | 0 | 0 |
| 2022 | 5 | 273 | 0 | 0 |
| 2023 | 10 | 229 | 0 | 0 |
| 2024 | 2 | — | 0 | 1 |
| 2025 | 14 | 210 | 0 | 2 |
| 2026 | 7 | 128 | 0 | — |
What is it indicated for?
VisiRad XR is a computer-aided detection (CADe) device intended to identify and mark regions of interest that may be suspicious for lung nodules and masses on chest radiographs. It identifies features associated with pulmonary nodules and masses from 6-60mm in size. Detection of suspicious findings by VisiRad XR is intended as an aid only after the physician has performed an initial interpretation; it is not intended to replace the review by a qualified…
Read the full statement (118 words)
VisiRad XR is a computer-aided detection (CADe) device intended to identify and mark regions of interest that may be suspicious for lung nodules and masses on chest radiographs. It identifies features associated with pulmonary nodules and masses from 6-60mm in size. Detection of suspicious findings by VisiRad XR is intended as an aid only after the physician has performed an initial interpretation; it is not intended to replace the review by a qualified radiologist and is not intended to be used for triage or to make or confirm a diagnosis. The intended patient population for VisiRad XR consists of patients >21 years of age on whom chest radiographs have been acquired in an outpatient or emergency department setting.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K223133 · printed Nov 6, 2026
Cite this page
510(k) Report. “K223133: VisiRad XR.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K223133
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026